Progressive and Sustained Disease Control in Patients with Atopic Dermatitis (AD) Aged 12–17 Years Treated with Tralokinumab for 52 Weeks. (2024). SKIN The Journal of Cutaneous Medicine, 8(2), s377. https://doi.org/10.25251/skin.8.supp.377